Health systems sits at the center of this dementia and brain health question.
Health systems across the country are joining forces through coordinated care networks, shared research initiatives, and collaborative infrastructure to accelerate Alzheimer’s treatment development and ensure patients have faster access to cutting-edge therapies. The Dementia Care Navigation Roundtable (DCNR), which brings together health systems, payers, and dementia experts, is establishing consistent protocols for dementia care navigation nationwide—a foundational shift that allows individual hospitals and health networks to implement standardized approaches rather than working in isolation. In 2026, the Alzheimer’s Association released a comprehensive white paper specifically designed to help healthcare organizations build and expand dementia care programs, particularly for health systems transitioning to value-based care models, signaling that collaboration is no longer optional but essential for delivering effective Alzheimer’s care.
This collaborative momentum is especially critical now because the field is moving faster than it has in decades. The pipeline includes 138 drugs being assessed across 182 clinical trials, with 102 of those drugs targeting the underlying disease mechanisms rather than just managing symptoms. This article explores how health systems are organizing themselves to benefit from these advances, what treatments are available today, which promising therapies are expected to reach patients in 2026, and how early detection is changing the landscape of Alzheimer’s prevention.
Table of Contents
- What Are Health Systems Doing to Collaborate on Alzheimer’s Treatments?
- The Clinical Trial Pipeline—Where New Treatments Come From
- FDA-Approved Treatments Reshaping Early Intervention
- Advanced Diagnostics—Finding Alzheimer’s Before Symptoms Begin
- Emerging Approaches and Their Promise
- Emerging Cellular and Molecular Approaches
- What’s on the Horizon for 2026 and Beyond
- Conclusion
- Frequently Asked Questions
What Are Health Systems Doing to Collaborate on Alzheimer’s Treatments?
The shift toward collaborative dementia care represents a fundamental reorganization of how American health systems approach one of the most costly and complex conditions they treat. Rather than each hospital network developing its own fragmented approach, the Dementia Care Navigation Roundtable is establishing coordinated models that allow patients to move seamlessly between primary care, specialists, imaging centers, and support services. This matters because Alzheimer’s diagnosis and treatment require coordination across multiple specialties—primary care physicians must identify early signs, neurologists must confirm diagnosis, imaging centers must perform PET scans or MRIs, and care coordinators must connect patients with resources. When these pieces work independently, patients often face delays, repeated testing, or missed opportunities for early intervention. The Alzheimer’s Association’s 2026 white paper on health system dementia care programs provides a roadmap for this transition, especially for systems moving away from traditional fee-for-service models toward value-based arrangements where payment is tied to outcomes rather than volume of services.
Health systems that adopt these coordinated protocols are positioning themselves to improve patient outcomes while reducing the total cost of dementia care—a critical consideration given that Alzheimer’s disease costs the healthcare system over $300 billion annually. However, implementing these networks requires upfront investment in staff training, care coordinator positions, and health IT infrastructure, which means smaller health systems or those in resource-constrained communities may lag behind in adoption. One concrete example of this collaboration in action is how health systems are coordinating access to disease-modifying treatments like lecanemab and donanemab. These drugs work best when started early in the disease course, so organized screening protocols, shared diagnostic capacity, and coordinated infusion center networks make the difference between a patient getting treated within the critical window or missing the opportunity entirely. Regional health systems that have established these networks report significantly higher rates of early identification and treatment initiation.
The Clinical Trial Pipeline—Where New Treatments Come From
The scale of the current Alzheimer’s drug development pipeline is unprecedented. There are 138 drugs being evaluated across 182 active clinical trials, with 102 of those drugs representing disease-targeted treatments—drugs designed to attack the underlying biological processes of Alzheimer’s rather than simply alleviating symptoms like agitation or sleep disturbance. This 74% rate of disease-targeted drugs in the pipeline represents a fundamental shift in how the field approaches Alzheimer’s, moving away from symptomatic management toward prevention and disease modification. Understanding the trial landscape is important because not all drugs move through development at the same pace, and the timeline from promising early-stage research to FDA approval typically spans 10 to 15 years.
The current pipeline includes treatments at every stage: some are in early Phase 1 safety testing, others are in Phase 3 trials with hundreds or thousands of participants, and some are awaiting FDA review decisions. This diversity of approaches—traditional pharmaceutical compounds, repurposed existing drugs, device-based interventions, and even immunotherapy—reflects the field’s recognition that Alzheimer’s likely has multiple contributing mechanisms that may require multiple therapeutic approaches rather than a single cure. A limitation worth noting is that clinical trial participation remains concentrated in academic medical centers and specialized research hospitals, leaving many rural and underserved communities underrepresented in the data that drives treatment development. This means that treatments developed and proven effective in urban trial populations may not perform identically in more diverse populations or in community hospital settings where resources and patient demographics differ significantly.
FDA-Approved Treatments Reshaping Early Intervention
Two disease-modifying therapies have already cleared FDA approval and are now available to eligible patients: lecanemab (marketed as Leqembi) and donanemab (marketed as Kisunla). Both drugs are monoclonal antibodies that target amyloid-beta, the protein that accumulates in the brains of Alzheimer’s patients, and both have demonstrated the ability to delay cognitive decline by approximately seven months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. While seven months may not sound dramatic, this represents a meaningful slowing of decline that can preserve independence and quality of life, particularly for people in their 60s and early 70s who still have decades of active life ahead. The practical implementation of these treatments has evolved significantly. Both require regular infusions or injections—initially requiring IV infusions at medical centers every two to four weeks, but more recently, the FDA approved an at-home injectable form of Leqembi for continued treatment.
This shift toward at-home administration is expanding access and reducing the burden on patients and caregivers who might otherwise need to travel to infusion centers regularly. The FDA is expected to make a decision by May 2026 on whether to approve initial starter doses for home administration as well, which would make the entire treatment regimen accessible from home. However, there are important limitations and considerations. These drugs are only approved for people with mild cognitive impairment or mild dementia—not for people with moderate or severe Alzheimer’s disease where more advanced cognitive decline has already occurred. Additionally, both drugs carry a risk of amyloid-related imaging abnormalities (ARIA), which can appear on brain MRI as microhemorrhages or microinfarcts, and require regular monitoring with MRI scans to ensure safety. For some patients, the burden of monthly MRIs adds complexity and cost to treatment.
Advanced Diagnostics—Finding Alzheimer’s Before Symptoms Begin
One of the most significant breakthroughs in recent years is the emergence of blood-based biomarkers that can identify Alzheimer’s disease at the earliest stages. An FDA-approved blood test is now available that can detect amyloid-beta accumulation in people over 55 who are experiencing symptoms or cognitive concerns. This represents a fundamental change in how clinicians approach diagnosis—rather than relying solely on cognitive testing, imaging, or the slow accumulation of clinical evidence, physicians can now order a simple blood test that identifies Alzheimer’s pathology with high accuracy. For patients and families, this means faster diagnosis, fewer repeated visits, and the ability to start disease-modifying treatment much earlier in the disease course. Even more remarkably, University of California researchers have developed a machine learning model that can predict Alzheimer’s disease up to seven years before any symptoms appear.
This model uses multiple biomarkers and imaging data to identify people at extremely high risk of developing cognitive decline, opening the possibility of preventative treatment strategies. The AHEAD Study is already testing this approach, using the disease-modifying drug Leqembi in cognitively normal people who have elevated amyloid levels but haven’t yet developed any memory or thinking problems. If successful, this would represent the first truly preventative approach to Alzheimer’s disease. The caveat here is that predictive models trained on certain populations—typically well-resourced, well-educated, and racially homogeneous groups—may not perform equally well across different populations. Additionally, identifying people at risk for disease seven years before symptoms raises complex questions about how to counsel patients about results, whether people want to know they may develop Alzheimer’s decades in the future, and how insurance and employment discrimination concerns might affect participation in preventative programs.
Emerging Approaches and Their Promise
Beyond the currently approved treatments, several cutting-edge approaches are in advanced development and expected to produce results or FDA decisions in 2026. Axsome Therapeutics’ AXS-05, designed to treat agitation in Alzheimer’s disease patients, is expected to receive an FDA decision by April 30, 2026. While agitation might sound like a minor symptom, it’s one of the most disruptive behavioral problems in dementia care, often leading to premature nursing home placement and reducing quality of life for both patients and caregivers. A safe, effective treatment for agitation could dramatically improve daily life for thousands of families. AriBio’s AR1001 represents a different kind of innovation—repurposing an existing drug class.
The company is testing whether a modified form of medication used for erectile dysfunction might slow Alzheimer’s disease progression through a novel mechanism. The Phase 3 trial includes over 1,500 participants and is expected to report results in the latter half of 2026. Repurposing existing drugs is valuable because these compounds have known safety profiles and established manufacturing processes, potentially accelerating time to market and reducing costs. Perhaps the most unconventional approach comes from Cognito Therapeutics with their SPECTRIS headset—a medical device using flickering light and sound stimulation at specific frequencies to potentially strengthen neural networks and slow cognitive decline. A 670-person Phase 3 trial is expected to finish in June 2026. The appeal of a device-based approach is that it avoids systemic drug exposure and its associated side effects, though the question remains whether the effects are durable and whether patients will consistently use the device as required.
Emerging Cellular and Molecular Approaches
Beyond traditional pharmaceuticals and devices, researchers are exploring fundamentally new approaches at the cellular level. CAR-T cell therapy, a technique initially developed for treating certain cancers, has shown promise in research studies by reducing amyloid plaques, decreasing brain immune cell activation, and protecting nerve cells from damage. CAR-T therapy works by engineering a patient’s own immune cells to target and eliminate disease-causing proteins—in this case, amyloid-beta. While still experimental, early results suggest this approach could be transformative for people with Alzheimer’s disease.
A specific advantage of CAR-T therapy is that it may provide durable benefit from a single treatment, unlike daily medications. Lithium, a medication used for decades in psychiatry, has also emerged as a research focus. August 2025 research indicated that lithium might have the potential to prevent or reverse Alzheimer’s disease damage in the brain through multiple mechanisms. While these early findings are promising, lithium requires careful monitoring of blood levels and kidney function, and it’s not yet clear whether the doses that would be effective for Alzheimer’s prevention can be safely given long-term without medical complications.
What’s on the Horizon for 2026 and Beyond
The convergence of collaborative health system infrastructure, a robust pipeline of clinical trials, emerging diagnostic tools, and multiple treatment approaches is creating genuine momentum in Alzheimer’s care. 2026 is shaping up to be a pivotal year with multiple regulatory decisions, trial results, and potential new treatment approvals expected. Health systems that have adopted the coordinated care models outlined in the Alzheimer’s Association’s 2026 white paper will be best positioned to rapidly integrate these new treatments into clinical practice and ensure patients have fast-track access.
Looking further ahead, the field is moving toward a model where Alzheimer’s disease is identified and treated in its preclinical and early clinical stages through blood-based screening, confirmed by advanced biomarkers, and managed through coordinated, multidisciplinary health system networks. Prevention and early intervention—rather than managing advanced disease—will become the norm. The biggest challenge in the coming years will be ensuring that these advances benefit all populations and communities, not just those with access to academic medical centers and well-resourced health systems.
Conclusion
Health systems are actively reorganizing themselves to take advantage of an unprecedented acceleration in Alzheimer’s disease treatment and diagnosis. Through initiatives like the Dementia Care Navigation Roundtable and the implementation of evidence-based care protocols outlined in the Alzheimer’s Association’s white paper, health networks are creating the infrastructure needed for rapid identification of patients at risk, early diagnosis, and timely initiation of disease-modifying therapies. The combination of FDA-approved treatments, advanced blood-based diagnostics, emerging cellular therapies, and a robust clinical trial pipeline creates a genuine sense that Alzheimer’s disease is transitioning from a diagnosis with no effective treatments to a condition that can be detected early and managed effectively.
The next step for patients and families is to work with their healthcare providers to understand whether they or their loved ones might benefit from screening or early intervention. For health systems still in the early stages of implementing coordinated dementia care programs, the 2026 Alzheimer’s Association white paper provides a concrete roadmap. The opportunities to prevent or slow Alzheimer’s disease are more real than ever before, but only if patients are identified early enough and if health systems have the infrastructure in place to deliver these advances efficiently and equitably.
Frequently Asked Questions
At what age should someone consider Alzheimer’s screening with the new blood tests?
The FDA-approved blood test is available for anyone over 55 who is experiencing symptoms or cognitive concerns—either reported by the individual or observed by family or physicians. If you’re experiencing memory problems, difficulty with complex tasks, or concerns about thinking, discussing blood-based biomarker testing with your primary care physician is reasonable.
How much longer might lecanemab or donanemab extend cognitive function?
These drugs have demonstrated the ability to slow cognitive decline by approximately seven months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. This means someone taking the drug might maintain their current level of cognitive function several months longer than someone not taking it.
Are these new Alzheimer’s treatments covered by Medicare or insurance?
Coverage policies vary by insurance plan. Lecanemab and donanemab have been approved by Medicare for eligible beneficiaries, but coverage may include prior authorization requirements and ongoing MRI monitoring costs. Contact your insurance provider for specific coverage details.
What is the AHEAD Study and should I consider participating?
The AHEAD Study is testing whether early treatment with Leqembi in cognitively normal people with elevated amyloid levels can prevent Alzheimer’s disease symptoms. If you’re interested in preventative Alzheimer’s research, your neurologist can provide information about clinical trial opportunities in your area.
How will I know if I have amyloid or tau accumulation in my brain?
Blood-based biomarker tests can now identify amyloid-beta accumulation with a simple blood draw. If results are positive, your physician may recommend PET imaging or additional tests to confirm and quantify the level of pathology.
What should I do if my doctor mentions I might be at risk for Alzheimer’s?
Have a detailed conversation with your physician about your specific risk factors, what screening or preventative options are available, and whether clinical trial participation might be appropriate for you. Discuss the benefits and limitations of early diagnosis and preventative treatment.
You Might Also Like
- Sorority Partners With National Organization to Address Brain Health Disparities
- Scientists Explain How Existing Alzheimer’s Drug Clears Brain Plaques
- Researchers Propose Fundamental Shift in Alzheimer’s Treatment Strategy
For more, see Alzheimer’s Association — clinical trials.
